NCT00081484View on ClinicalTrials.gov

A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Anemia
Interventions
DRUG

epoetin alfa or beta

iv or sc, as prescribed

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks

Trial Locations (66)

100

Taipei

407

Taichung

833

Kaohsiung City

10025

New York

11355

Flushing

13616

Aix-en-Provence

14127

Orchard Park

16502

Erie

17044

Lewistown

19106

Philadelphia

19140

Philadelphia

19141

Philadelphia

22100

Como

22908

Charlottesville

27100

Pavia

28007

Madrid

29209

Columbia

33617

Tampa

38801

Tupelo

39705

Columbus

41100

Modena

44093

Nantes

44109

Cleveland

44195

Cleveland

49007

Kalamazoo

60473

South Holland

63128

St Louis

70884

Baton Rouge

71101

Shreveport

71103

Shreveport

73011

Chambéry

75970

Paris

76031

Rouen

80804

München

83400

Hyères

90073

Los Angeles

90431

Nuremberg

90720

Los Alamitos

91054

Erlangen

91723

Covina

92123

San Diego

92161

San Diego

94275

Le Kremlin-Bicêtre

96813

Honolulu

97045

Oregon City

02135

Boston

07601

Hackensack

23507-1901

Norfolk

K1H 7W9

Ottawa

M5G 2C4

Toronto

J4V 2H1

Greenfield Park

H3G 1A4

Montreal

35-055

Rzeszów

02-006

Warsaw

2799-523

Carnaxide

4099-001

Porto

2910-446

Setúbal

00732

Ponce

00936-5067

San Juan

03010

Alicante

Unknown

Bangkok

G4 OSF

Glasgow

SG1 4AB

Hertford

E1 1BB

London

M6 8HD

Salford

SA6 6NL

Swansea

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00081484 - A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients | Biotech Hunter | Biotech Hunter